Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC. (Q39598004)

13 September 2017

Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC. (English)

1 reference

13 September 2017

1 reference

Christina Battke

1

1 reference

13 September 2017

Romana Ruiss

2

1 reference

13 September 2017

Ulrich Welsch

3

1 reference

13 September 2017

Pauline Wimberger

4

1 reference

13 September 2017

Stephan Lang

5

1 reference

13 September 2017

Simon Jochum

6

1 reference

13 September 2017

Reinhard Zeidler

7

1 reference

13 September 2017

language of work or name

1 reference

4 February 2011

1 reference

Cancer Immunology, Immunotherapy

13 September 2017

1 reference

13 September 2017

60

1 reference

13 September 2017

639-648

1 reference

13 September 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-011-0979-5

13 September 2017

0 references

cites work

Immunosuppressive strategies that are mediated by tumor cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Human tumor-derived exosomes down-modulate NKG2D expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Malignant effusions and immunogenic tumour-derived exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

A systematic review of humoral immune responses against tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

HER2 as a target for breast cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Lipid raft-associated protein sorting in exosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

B lymphocytes secrete antigen-presenting vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Tumor-released microvesicles as vehicles of immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Tumour-released exosomes and their implications in cancer immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Mechanism of action of trastuzumab and scientific update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Microfluidic isolation and transcriptome analysis of serum microvesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Immunogenic regions of the GA733-2 tumour-associated antigen recognised by autoantibodies of patients with colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

FcRgamma activation regulates inflammation-associated squamous carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Trastuzumab resistance: role for Notch signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0979-5

10.1007/S00262-011-0979-5

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference